灵康药业 (603669)

Lionco Pharmaceutical Group Co., Ltd.

ASH

Tags

Contract Research Organization (CXO)Innovative DrugsChemical PharmaceuticalsPharmaceutical ManufacturingPharmaceuticals and HealthcareContains Convertible BondsPrivate HospitalsNew Private Equity Holdings

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 72124.48
  • Circulating A-Shares(W): 72124.48
  • Earnings Per Share(RMB): -0.0478
  • Net Assets Per Share(RMB): 0.9356
  • Operating Revenue(W RMB): 28186.07
  • Total Profit(W RMB): -3450.28
  • **Net Profit Attributable to Parent(W RMB) **: -3450.31
  • Net Profit Growth Rate(%): 26.42
  • Weighted Return on Equity(%): -4.5900
  • Operating Cash Flow Per Share(RMB): -0.1640
  • Undistributed Profit Per Share(RMB): -0.4731
  • Capital Reserve Per Share(RMB): 0.3642

2. Main Business

The main business covers:

  • Research, development, production, and sales of chemical prescription drugs

3. Company Basic Information

  • Company Name: Lingkang Pharmaceutical Group Co., Ltd.
  • Listing Date: 2015-05-28
  • Industry: Pharmaceutical Manufacturing
  • Address: First Floor, Building 2, Naidong County Commercial and Residential Building, 68 Naidong Road, Zedang Town, Shannan City, Tibet Autonomous Region
  • Website: https://www.lingkang.com.cn
  • Company Profile: The company's predecessor was Hainan Lingkang Pharmaceutical Co., Ltd., established on December 24, 2003. In October 2012, Lingkang Limited was transformed into Hainan Lingkang Pharmaceutical Group Co., Ltd. based on the net assets audited by Tianjian Firm as of July 31, 2012, converted into 19,500 million shares. All assets, liabilities, business, and personnel of Lingkang Limited were inherited by the transformed joint-stock company. On October 16, 2012, the Hainan Administration for Industry and Commerce issued the "Business License". On December 18, 2013, the company relocated to Shannan, Tibet and changed its name to "Tibet Lingkang Pharmaceutical Group Co., Ltd.". On March 12, 2014, the company was renamed "Lingkang Pharmaceutical Group Co., Ltd.".

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Lingkang Holding Group Co., Ltd. General Legal Person 33965.28 47.09
2 Shanghai Danyin Investment Management Center (Limited Partnership) - Danyin Preferred No. 1 Private Securities Investment Fund Private Securities Investment Fund 253.30 0.35
3 Beijing Great Times Private Fund Management Co., Ltd. - Great Times Mama 77 Private Securities Investment Fund Private Securities Investment Fund 196.40 0.27

5. Concept Sectors

  • Convertible Bonds
  • Private Hospitals
  • CXO Concept
  • Innovative Drugs
  • Consecutive Losses
  • New Private Placements

Remarks

  • Data update date: 2025-09-30
  • Data source: Public Market Information